1. Introduction
===============

Tablet splitting is a widely practiced phenomenon resulting from the need to alter and optimise medicine doses in individual patients. Almost a quarter of all drugs administered in primary care are split.^\[[@R1]\]^ This may be required for patients to overcome dysphagia caused by large tablets.^\[[@R2]\]^ It facilitates swallowing of the tablet and increases compliance as it eases consumption of the tablet.^\[[@R3],[@R4]\]^ This practice can be relatively unproblematic if the patient ingests all fragments to deliver the desired dose.^\[[@R5]\]^ Additionally, tablet splitting is used as a cost-saving practice.^\[[@R1],[@R6]\]^ For example, treatment prices for drugs administered in primary care were reduced by up to 45% especially where the price per tablet does not proportionally increase with increasing dose strength.^\[[@R1]\]^ Splitting for these reasons is a common part of current drug therapy.

Dose inaccuracy may be a consequence of inaccurate splitting or loss of tablet weight during the process of splitting.^\[[@R7]\]^ The resulting variation in drug mass and content may lead to adverse effects ranging from toxicity to loss of efficacy.^\[[@R8]\]^ This is especially important for drugs with dose-dependent effects or narrow therapeutic index and short half-life.^\[[@R9]\]^

Split fragments should comply with the content or mass uniformity requirements.^\[[@R10],[@R11]\]^ Brand-specific product information is available on drug package leaflets which may include information on suitability of the specific tablet to be split. Unfortunately, this guidance is frequently disregarded.^\[[@R12]\]^ Additionally, hospitals often have their own specific drug formularies and accompanying drug information. However, these sources are often in conflict. This acts as a source of confusion for the patients, prescribers, pharmacists and nurses and warrants attention. There is a need for standardised documentation and information regarding tablet splitting.

There is limited guidance on tablet splitting. A Swiss study reported that official sources of drug information for the majority of scored tablets contained no explicit information on tablet splitting.^\[[@R5]\]^ Thus, given the variation between methods for splitting tablets such as using hands, tablet splitters and knives or scissors, and the variable physical characteristics of tablets, such as presence of a score line, can potentially produce differences in the resultant segments, and consequently, the dosage.^\[[@R13],[@R14]\]^

Although dose manipulation is common practice, currently there is limited literature summarising the evidence available on splitting a tablet and obtaining the correct dose. Past reviews have focused on either a specific population, drug, or disease.^\[[@R15],[@R16]\]^ The aim of this study is to summarise the literature measuring the effect on dose accuracy associated with splitting a tablet without limiting data sources to population, disease or drug specific studies.

2. Methods
==========

The systematic review described within this protocol will be reported as per Preferred Reporting Items for Systematic Review and Meta-Analysis for protocol (PRISMA-P) recommendations. This study is registered on PROSPERO, an international register of systematic reviews (CRD42018106252).

2.1. Eligibility criteria
-------------------------

### 2.1.1. Study design

We will exclude case studies, reports and letters. However, there will be no further restriction on study design to assess the effects of splitting a tablet. Data will also be used from laboratory-based tablet splitting studies where the drug was not administered to a patient as these studies can consider the weight or drug content of the split drug. Therefore, studies investigating any drug, where the tablet was split, will be potentially eligible. This review will include studies from the beginning of databases till January 2020.

Publications must contain sufficient detail to be included within the review, therefore, conference abstracts will be excluded from analysis. However, study authors will search databases for publications relating to the abstract.

### 2.1.2. Types of participants

There will be no restriction in participant characteristics. Participants will be included regardless of their age or experience with tablet splitting.

### 2.1.3. Types of interventions and comparators

Interventions will include manipulation of oral tablets (excluding capsules). Manipulation can include splitting, cutting or breaking tablets into smaller sections. Comparator is the whole, unbroken tablet.

### 2.1.4. Study outcomes

The primary outcome is to assess the dose accuracy of the split drug either by weight or drug content. The secondary outcomes are to assess variation in dose accuracy between methods for splitting as well as physical characteristics, differences in health outcomes when ingesting split tablet and patient satisfaction from using the split tablet. The study must assess primary outcome to be eligible for the review.

2.2. Search strategy
--------------------

This systematic review will involve a search of MEDLINE, EMBASE, CINAHL, and Cochrane databases. Any study published from the start of the databases prior to January 2020 will be included in the review.

The search strategy will capture studies that include key words outlined below.

1.  Intervention: (tablet∗ split∗ or tablet∗ break∗ or tablet∗ cut∗ or tablet∗ manipulat∗).mp. \[mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms\]

2.  Primary outcome: (pill∗ split∗ or pill∗ break∗ or pill∗ cut∗ or pill∗ manipulat∗).mp. \[mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms\]

Additionally, further studies will be obtained from scanning reference lists of included studies and citation searching of key papers. This will ensure the maximum number of relevant articles are included within the review.

2.3. Data management
--------------------

After searching, the shortlisted articles were exported to Endnote X9 (Thomson Reuters, NY) for storage of study records, abstracts and full text articles. Articles will be stored on a password protected server-based platform that is accessible to both reviewers. At each stage of the article selection process (e.g., after consolidation of all articles prior to assessing eligibility based on title and abstract), back up files of the Endnote database will be made in order to retrace any steps as needed in the review process.

2.4. Selection process
----------------------

Two researchers will undertake the selection of studies process separately to reduce the risk of bias. In the initial screening stage, these authors will conduct a title search and identify abstracts which potentially meet the criteria for study selection. For papers where it is unclear whether the study should be included, a further assessment against the criteria will be undertaken, using the full text of these articles. This will be done independently to reduce risk of bias. Discrepant opinions between two reviewers will be resolved in discussion with the senior author. The flow of studies through selection process, together with reasons for exclusion at the full-text review stage will be reported using a modified PRIMSA diagram.

2.5. Data collection process
----------------------------

Once the studies for inclusion are identified, information outlined in the standardised data extraction form will be collected. Data from all included studies will be extracted. The form will be piloted and optimised by the two reviewers using a subset of five randomly selected studies that satisfy the eligibility criteria. One author will independently extract data from the remainder of the included studies. The data extracted will be verified by a second reviewer.

2.6. Data items
---------------

The following data will be extracted from the included studies:

1.  General study information: study title, study authors, year of publication, and citation.

2.  Characteristics of the study: aim or objectives of the study, country in which study took place, study design, condition, and pharmacopeia referenced.

3.  Participant characteristics: numbers of participants, type of participants, prior experience, and instructions given.

4.  Tablet characteristics: tablet type, shape, score-line, diameter, coating, and weight.

5.  Intervention characteristics: type of tablet splitting method used and any parallel interventions implemented.

6.  Outcomes: result of primary outcome and statistical significance, documentation of specific quantitative and qualitative secondary outcomes of interest, risk of bias assessment, and overall study conclusion.

2.7. Risk of bias in individual studies
---------------------------------------

For randomised controlled trials (RCTs) included within this review, the risk of bias will be ascertained by two reviewers in parallel using The Cochrane Risk of Bias Tool.^\[[@R17]\]^ The Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) system will be used to summarise the quality of evidence for each outcome.^\[[@R18]\]^

Developing a unique quality assessment tool (Table [1](#T1){ref-type="table"}) using known quality tools and study specific additions will allow us to assess the quality of these studies. The items within this form will be categorised as 'Yes', 'No', or 'Unclear'. This form draws on aspects of the Strengthening the Report of Observational Studies in Epidemiology (STROBE) checklist.^\[[@R19]\]^ This will ensure mapping of evidence and identification of research gaps within this field. Additionally, the items addressing data collection and analysis will be based on European, British, and United States Pharmacopoeia. The form will be piloted and adjusted prior to being applied to all studies.

###### 

Quality appraisal tool to be used for the systematic review described within this protocol.

![](medi-98-e17189-g001)

2.8. Data synthesis and analysis
--------------------------------

Studies will be included in the data synthesis if they fulfil the eligibility criteria. Data will be presented in a descriptive narrative and supplemented with tables and figures where appropriate.

If deemed feasible (i.e., variables assessed in the selected papers are comparable and there is sufficient data) we aim to perform meta-analyses of proportions with both fixed effect (Inverse Variance) and random effects models (using the method of DerSimonian and Laird). A continuity correction of 0.5 will be applied in case of numerators equal to zero and the Wilson Score method will be used to calculate confidence intervals bounded to 0 and 1. We also intend to perform subgroup meta-analyses according to method of splitting and physical tablet characteristics. All statistical analyses will be performed using Stata 15 (StataCorp LLC, College Station, TX) with the metaprop function.^\[[@R20]\]^

2.9. Patients and public involvement
------------------------------------

Patients and public were not involvement in writing this protocol.

3. Discussion
=============

Tablet splitting is a common practice arising from the need to alter and optimise medicine doses in individual patients, but earlier studies recommend avoiding tablet splitting due to inaccuracy.^\[[@R21]\]^ Currently, there is limited literature summarising the evidence available on splitting a tablet and obtaining the correct dose. Consequently, the planned systematic review will synthesise evidence surrounding tablet splitting and dose accuracy.

There will be potential limitations of this review. Developing a search strategy was difficult as 'tablet splitting' does not have a standard term or clear definition within databases therefore, there was potential for relevant articles to be missed. The search strategy developed needed to be balanced between being sensitive, yet precise, within the papers extracted. Despite these efforts, it is possible that a large number of irrelevant references may still be retrieved which is unavoidable with search terms that are not drug or intervention specific.

Additionally, as this review is not limited to RCTs the nature of studies that may be eligible raises challenges when assessing quality of these studies. Laboratory based studies do not generally feature in systematic reviews, thus are not considered in the available quality assessment tools. We developed our own quality appraisal tool to determine the quality of such studies. Although there are limitations to this tool, systematic reviews that include a broad range of study designs either do not report on quality^\[[@R15]\]^ or have also undertaken a similar approach.^\[[@R16],[@R22]\]^ Very few of these reviews have published their grading tool, with those that are published focusing on quality of the publication rather than the quality of the study itself.^\[[@R23]\]^

3.1. Ethics and dissemination
-----------------------------

This study does not require ethics approval. The results of the systematic review described within this protocol will be presented at relevant conferences and published in a peer-reviewed journal. It should be noted that prescribers should follow manufacturer\'s instructions when splitting tablets and this review should be used as a guide. The review described within this protocol will be of interest to healthcare professionals, physicians, and pharmacists in particular, as well as people who use tablets. The methods can be used to inform future reviews exploring the effect of tablet cutting on dose accuracy. Approaches to overcome the identified challenges serve to illustrate that thorough review of current literature is required to make an assessment on the potential of splitting tablets to gain the required dose.
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